University of Wollongong
Browse

Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea

Download (699.82 kB)
journal contribution
posted on 2024-11-15, 21:18 authored by Peter Eastwood, Maree Barnes, Stuart Mackay, John Wheatley, David Hillman, Xuan-Lan Nguyen, Richard Lewis, Matthew Campbell, Boris Petelle, Jennifer Walsh, Andrew C Jones, Carsten Palme, Alain Bizon, Nicole Meslier, Chloe Bertolus, Kathleen Maddison, Laurent Laccourreye, Guillaume Raux, Katleen Denoncin, Valerie Attali, Frederic Gagnadoux, Sandrine Launois
Background and aim Hypoglossal nerve stimulation (HNS) decreases obstructive sleep apnoea (OSA) severity via genioglossus muscle activation and decreased upper airway collapsibility. This study assessed the safety and effectiveness at 6 months post-implantation of a novel device delivering bilateral HNS via a small implanted electrode activated by a unit worn externally, to treat OSA: the Genio™ system. Methods This prospective, open-label, non-randomised, single-arm treatment study was conducted at eight centres in three countries (Australia, France and the UK). Primary outcomes were incidence of device-related serious adverse events and change in the apnoea–hypopnoea index (AHI). The secondary outcome was the change in the 4% oxygen desaturation index (ODI). Additional outcomes included measures of sleepiness, quality of life, snoring and device use. This trial was registered with ClinicalTrials.gov, number NCT03048604. Results 22 out of 27 implanted participants (63% male, aged 55.9±12.0 years, body mass index (BMI) 27.4±3.0 kg·m−2) completed the protocol. At 6 months BMI was unchanged (p=0.85); AHI decreased from 23.7±12.2 to 12.9±10.1 events·h−1, a mean change of 10.8 events·h−1 (p<0.001); and ODI decreased from 19.1±11.2 to 9.8±6.9 events·h−1, a mean change of 9.3 events·h−1 (p<0.001). Daytime sleepiness (Epworth Sleepiness Scale; p=0.01) and sleep-related quality of life (Functional Outcomes of Sleep Questionnaire-10; p=0.02) both improved significantly. The number of bed partners reporting loud, very intense snoring, or leaving the bedroom due to participant snoring decreased from 96% to 35%. 91% of participants reported device use >5 days per week, and 77% reported use for >5 h per night. No device-related serious adverse events occurred during the 6-month post-implantation period. Conclusions Bilateral HNS using the Genio™ system reduces OSA severity and improves quality of life without device-related complications. The results are comparable with previously published HNS systems despite minimal implanted components and a simple stimulation algorithm.

History

Citation

Eastwood, P., Barnes, M., MacKay, S., Wheatley, J., Hillman, D., Nguyen, X., Lewis, R., Campbell, M., Petelle, B., Walsh, J., Jones, A., Palme, C., Bizon, A., Meslier, N., Bertolus, C., Maddison, K., Laccourreye, L., Raux, G., Denoncin, K., Attali, V., Gagnadoux, F. & Launois, S. (2020). Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea. The European respiratory journal, 55 (1), 1901320-1-1901320-11.

Language

English

RIS ID

141009

Usage metrics

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC